|
Isaac Kohane, MD, PhDMarion V. Nelson Professor and Chair, Department of Biomedical Informatics, Harvard Medical School Isaac “Zak” Kohane joined the New England Journal of Medicine as a member of the editorial board in 2019 where he focused on the evaluation of investigations that used artificial intelligence (AI) methodologies. He is committed to making NEJM AI a trusted authority for promoting the use of safe, unbiased, and efficacious AI applications to clinical medicine by setting the standard for rigorous and transparent clinical evaluations. Zak is the Marion V. Nelson Professor and the inaugural Chair of the Department of Biomedical Informatics at Harvard Medical School, where he works on using computational techniques to instrument health care systems as living laboratories. He also uses machine learning techniques and multimodal measurements to better diagnose and understand complex disorders such as autism. Zak completed a fellowship and residency in pediatrics at Boston Children’s Hospital. His current clinical focus is undiagnosed diseases. He completed a PhD in Computer Science during an earlier heyday of AI in medicine. Zak has published over 500 papers in the medical literature and is a member of the Institute of Medicine and the American Society for Clinical Investigation. A native of Geneva, Switzerland, Zak resides in Newton, Massachusetts and has a beautiful Belgian sheepdog to keep him company as his three children head off to college. |
|
Charlotte Haug, MD, PhDCharlotte J. Haug is a MD, PhD from the University of Oslo, Norway and a MSc in Health Services Research from Stanford University, United States. She is Executive Editor of NEJM AI, International Correspondent at the New England Journal of Medicine, Senior Scientist at SINTEF Digital Health (Norway), and Adjunct Affiliate of Stanford Health Policy, Stanford University. Dr. Haug has worked in clinical medicine and research in Norway and with organization, priority setting, and supervision of health care systems both nationally and internationally. From 2002–2015, she was Editor-in-Chief of the Journal of the Norwegian Medical Association and a member of the International Committee of Medical Journal Editors (ICMJE, the “Vancouver group”). She was a Council Member of the Committee on Publication Ethics (COPE) from 2005–2015 and Vice-Chair of COPE from 2012–2015. She received the Council of Science Editors (CSE) Award for Meritorious Achievement in 2013 and was on the International Advisory Board of the 4th World Conference on Research Integrity in Rio de Janeiro, Brazil, in 2015. She has worked extensively with issues concerning scientific publication, research, and publication ethics with a particular emphasis on how to handle and optimize the use of personal data collected in clinical and clinical research settings while preserving the individuals’ right to privacy. The application of AI in clinical medicine in a responsible and ethical way to avoid bias and hopefully provide more and better care to those who do not get the best care now, is a major interest going forward. |
|
Andrew Beam, PhDAssistant Professor, Department of Epidemiology, Harvard T.H. Chan School of Public Health Andrew Beam, PhD, is a founding Deputy Editor of NEJM AI and a co-host of the NEJM Group podcast AI Grand Rounds. Andrew is a long time AI optimist and is deeply committed to realizing an AI-enabled health care system that works for everyone. Andrew is an assistant professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health, with a secondary appointment in the Department of Biomedical Informatics at Harvard Medical School. His lab develops new AI methods by combining large scale deep learning models with techniques from causal inference to improve the safety and robustness for medical applications. He has a particular interest in using AI to improve neonatal and perinatal outcomes. Outside of the lab, Andrew lives in Waltham, MA, with his wife Kristyn, a neonatologist and frequent collaborator. They are currently focused on training their largest neural net to date: a 3-year-old named Hallie whose entropy maximization algorithm means never a shortage of things to clean up! |
|
Arjun (Raj) Manrai, PhDAssistant Professor, Department of Biomedical Informatics, Harvard Medical School Arjun “Raj” Manrai, PhD, joined the New England Journal of Medicine in 2022 as a founding Deputy Editor of NEJM AI. From Raj’s perspective, NEJM AI will help bridge the gap between the growing capabilities of AI and the evidence needed by clinicians to improve care. Raj is an Assistant Professor in the Department of Biomedical Informatics at Harvard Medical School, where he directs a research lab that works broadly on machine learning and statistical approaches to improve medical decision making. Focus areas for his group include the clinical use of genomic data and blood laboratory biomarkers, inherited heart disease and kidney disease, decision making across populations, and reproducibility challenges for medical AI. Raj took the scenic route to medical AI, earning an AB in Physics from Harvard College followed by a PhD in Bioinformatics and Integrative Genomics from the Harvard-MIT Division of Health Sciences and Technology (HST). He resides in the Boston area and outside work he can usually be found losing home dance competitions to his 2 young daughters. |
|
Lily Peng, MD, PhDDr. Peng is a physician-scientist and a director of product management at Verily, where she works on accelerating evidence generation through Verily’s Clinical Studies Platforms. Before Verily, she co-led Google Health AI in applying AI to enable better and more equitable care, particularly for diabetic eye disease, cardiovascular disease, and cancer. Her resulting papers have been published in JAMA, Nature, Nature Medicine, and Nature Biomedical Engineering. She graduated with an MD/PhD in Bioengineering from the University of California, San Francisco and a BS in Chemical Engineering from Stanford. She co-founded Nano Precision Medical, a drug delivery device start-up, and was a product manager at Doximity. She has been named in Fortune magazine’s 40 under 40 in health care, and Wired magazine’s list of 20 People Who Are Creating the Future. |
|
Xiaoxuan (Xiao) Liu, PhDDr. Xiaoxuan (Xiao) Liu is an Ophthalmologist and a Clinician Scientist at the University of Birmingham, UK. She co-leads the AI & Digital Health Research and Policy Group at University Hospitals Birmingham, and her work focuses on Responsible Innovation in AI health technologies by translating scientific evidence into best practice in research, policy, and regulation. Dr. Liu completed her PhD at the University of Birmingham, where she led the clinical validation of an imaging technique (automated analysis of OCT) for detecting inflammation in the eye. In 2020, she led the development of SPIRIT-AI and CONSORT-AI, reporting guidelines for AI clinical trials, which have been subsequently adopted by leading medical journals. Other notable work includes The Medical Algorithmic Audit framework for AI safety monitoring, which is being piloted into the NHS, and STANDING Together – an international effort to tackle bias in health data and medical AI technologies. Dr. Liu has experience working across sectors, including health care, academia, policy and industry, and has advised the WHO, the UK medical device regulator (MHRA) and health commissioner (NICE), and the NHS AI Lab on ensuring responsible use of AI for health. Her work has been featured in Wired, The Guardian, BBC Radio, The New Scientist and other news outlets, and recognized as Top Notable Advances of 2019 and 2020 by Nature Medicine. |
|
David Ouyang, MDAssistant Professor, Department of Cardiology, Division of AI in Medicine, Cedars-Sinai Medical Center David Ouyang, MD, is a cardiologist with a focus on cardiovascular imaging and a physician scientist focused on AI applications in cardiology. As a physician-scientist and statistician with clinical focus on cardiology and cardiovascular imaging, David works on applications of deep learning, computer vision, and large language models build on large datasets within cardiovascular medicine. As an echocardiographer, David ran the first blinded, randomized clinical trial of AI in cardiology, comparing the performance of AI assessment of LVEF vs. sonographers in a prospective, blinded assessment. His work has been published in Nature, Nature Medicine, and JAMA Cardiography, and is interested in the application of AI for democratizing equitable and accurate health care in cardiovascular medicine. David majored in statistics at Rice University, obtained his MD and UCSF, received post-graduate medical education in internal medicine, cardiology, and a postdoc in computer science and biomedical data science at Stanford University. David lives with his wife and son in Los Angeles, and in his free time likes flying drones and photography. |
|
Jianfei Zhao, PhDJianfei Zhao, PhD joined NEJM 医学前沿, a collaboration between the NEJM Group and J-Med, as a founding deputy editor in 2016. He is responsible for the editorial operations and strategies, academic conferences and clinical research training program. He collaborated with editors and other functions from the NEJM Group for numerous projects, including the annual Artificial Intelligence in Medicine Symposium (AIMS). Previously, he was a full-time scientific editor at Nature Communications, managing the evaluation and review of worldwide submissions in epigenetics, bioinformatics, and molecular biology methods, among other areas. He fostered close relationships with researchers and clinicians from a broad range of medical and life sciences in China. He obtained a BSc from Peking University and a PhD from the University of Oregon. His postdoctoral training in the U.S. National Cancer Institute was centered on the epigenetic regulation of gene expression. |
|
Euan Ashley, MB ChB, DPhil, Stanford University Euan Ashley is Associate Dean and Professor of Medicine and Genetics at Stanford University in California. Over the last decade his team has focused on the application of the human genome to medicine. He was recognized by the Obama White House for his contributions to Personalized Medicine and awarded the American Heart Association Medal of Honor for Genomic and Precision Medicine. His book The Genome Odyssey – Medical Mysteries and the Incredible Quest to Solve Them was released in 2021. He is co-founder of three companies: Personalis, DeepCell and SVEXA. Father to three young Americans, in his spare time, he tries to understand American football, plays jazz saxophone, and conducts research on the health benefits of single malt Scotch whisky. |
|
David Blumenthal MD, MPP, Harvard University David Blumenthal MD, MPP is Professor of Practice of Public Health at the Harvard Chan School of Public Health and a Research Fellow at the Harvard Kennedy School of Government. He is also Samuel O. Their Professor of Medicine, Emeritus, at Harvard Medical School. From 2013–2023, Dr. Blumenthal was president and CEO of the Commonwealth Fund, a health care philanthropy based in New York City with the mission of improving the functioning of the U.S. health care system. From 2009–2011 he was National Coordinator for Health Information Technology under President Obama. Prior to 2009, Dr. Blumenthal was a primary care physician at Massachusetts General Hospital and Director of the Institute for Health Policy at MGH and Harvard, which he founded. Dr. Blumenthal is an elected member of the National Academy of Medicine and a member of the editorial board of the New England Journal of Medicine, where he has also served as a National Correspondent. He has served previously on the boards of the University of Chicago and University of Pennsylvania health systems. He holds a Doctor of Humane Letters from Rush University and Honorary Doctor of Science from Claremont Graduate University and the State University of New York Downstate.
|
Noa Dagan, MD, PhD (Comp. Sci.), MPH, Clalit Noa Dagan is a public health physician and researcher. She holds an MD and an MPH from the Hebrew University, and a PhD in Computer Science from Ben-Gurion University. She completed her postdoc in the Department of Biomedical Informatics at Harvard Medical School. Dr. Dagan heads the AI-driven Medicine Department at Clalit Innovation (Clalit is Israel's largest integrated health care organization, covering over 50% of the Israeli population). Her responsibilities include the development and implementation of digital health care solutions to promote preventive, proactive, and personalized medicine. She leads the entire lifecycle of AI-driven interventions, from conception, through machine-learning modeling, to implementation in medical practice. Dr. Dagan is also the co-director of the Digital Health Lab at the department of Software and Information Systems Engineering at Ben-Gurion University. Her research focuses on prediction models, algorithmic fairness, and causal inference based on real-world data. | |
Judy Wawira Gichoya, MD, Emory University Dr. Gichoya is a multidisciplinary researcher, trained as both an informatician and a clinically active radiologist. She is an assistant professor at Emory University and works in Interventional Radiology and Informatics. She is seconded to the National Institutes of Health as a data scholar to help with the Open Data Science Platform (OSDP) component of the DSI Africa Initiative to “Harness Data Science for Health in Africa.” Her career focus is on validating machine learning models for health in real clinical settings, exploring explainability, fairness, and a specific focus on how algorithms fail. She has worked on the curation of datasets for the SIIM (Society for Imaging Informatics in Medicine) hackathon and ML committee. She volunteers on the ACR and RSNA machine learning committees to support the AI ecosystem to advance development and use of AI in medicine. | |
Carey Goldberg Carey Goldberg is a longtime health and science reporter who has also been the Boston bureau chief of the New York Times and Bloomberg News. In 2023, she co-authored The AI Revolution in Medicine: GPT-4 and Beyond with this journal’s Editor-in-Chief, Zak Kohane, and Peter Lee, Microsoft’s chief of research. Over the last two decades, Carey’s medical coverage for the Boston Globe, WBUR/NPR and Bloomberg ranged from health care costs to cancer research, from pandemic surges to polygenic risk scores. Her prizes have included an Edward R. Murrow innovation award for The Magic Pill, a podcast on the boundless benefits of exercise. Previously, Carey was a Pulitzer-finalist Moscow correspondent for the Los Angeles Times covering the collapse of the Soviet Union and its aftermath. She graduated summa cum laude from Yale, did graduate work at Harvard, and was a Knight Science Journalism fellow at MIT. | |
Chris Holmes, PhD, University of Oxford Chris Holmes is Professor of Biostatistics at the Departments of Statistics and Nuffield Department of Medicine, University of Oxford, and Programme Director for Health and Medical Sciences at the Alan Turing Institute, London, UK. Chris serves on the International Scientific Advisory Board for UK Biobank and the UK’s National Health Service (NHS) AI Award Evaluation Advisory Group. Chris is a founding member of the European Laboratory for Learning and Intelligent Systems (ELLIS) and co-director of the ELLIS Program in Robust Machine Learning. He is previous recipient of the Research Prize from the Royal Statistical Society and a Medallion awardee from the Institute for Mathematical Statistics (IMS). Chris’ interests are in theory, methods and applications of robust statistical machine learning and causal inference to addressing real-world problems in health. | |
Daphne Koller, PhD, Insitro Daphne Koller is CEO and Founder of insitro, a machine learning-driven drug discovery and development company. Daphne is also co-founder of Engageli, was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years, the co-CEO and President of Coursera, and the Chief Computing Officer of Calico Labs. She is the author of over 300 refereed publications with an h-index of 146. Daphne was recognized as one of TIME magazine’s 100 most influential people in 2012. She received the MacArthur Foundation Fellowship in 2004, the ACM Prize in Computing in 2008, the ACM AAAI Allen Newell Award in 2019, and the AnitaB.org Technical Leadership Abie Award Winner in 2022. She was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Association for Artificial Intelligence in 2004, the American Academy of Arts and Sciences in 2014, and the International Society of Computational Biology in 2017. | |
|
Lauren Oakden-Rayner, MBBS, University of Adelaide Dr. Lauren Oakden-Rayner (FRANZCR, PhD) is the Director of Research in Medical Imaging at the Royal Adelaide Hospital and is a senior research fellow at the Australian Institute for Machine Learning. Her research explores the safe translation of AI technologies into clinical practice, both from a technical and clinical perspective. |
Ziad Obermeyer, MD, UC Berkeley Ziad Obermeyer is Associate Professor and Blue Cross of California Distinguished Professor at UC Berkeley. He works at the intersection of machine learning and health. He is a Chan Zuckerberg Biohub Investigator, a Faculty Research Fellow at the National Bureau of Economic Research and was named an Emerging Leader by the National Academy of Medicine. His papers have appeared in a wide range of journals, including Science, Nature Medicine, New England Journal of Medicine, JAMA, and ICML, and have won awards from professional societies in medicine and economics. His work on algorithmic bias is frequently cited in the public debate about AI, and in federal and state regulatory guidance and investigations. He is a co-founder of Nightingale Open Science, a non-profit that makes massive new medical imaging datasets available for research, and Dandelion, a platform for AI innovation in health. Previously, he was a consultant at McKinsey & Co., and an Assistant Professor at Harvard Medical School. He continues to practice emergency medicine in underserved communities. | |
Pranav Rajpurkar, PhD, Harvard Medical School Pranav Rajpurkar is an Assistant Professor at Harvard Medical School leading a research lab working on developing AI technologies for medical applications. His lab has developed label-efficient deep learning algorithms that can read medical images at the level of experts, built large-scale open medical datasets, and demonstrated the effects of AI on medical decision making. Prof. Rajpurkar co-hosts The AI Health Podcast and co-edits the Doctor Penguin AI health newsletter. He instructed the Coursera course series on AI for Medicine and leads the joint Harvard-Stanford Medical AI Bootcamp Program. Previously, Prof. Rajpurkar received his BS, MS, and PhD degrees, all in Computer Science from Stanford University. | |
Wong Tien Yin, Tsinghua University Prof. Wong is a senior academic physician-scientist-innovator. He is currently Vice Provost at Tsinghua University and Founding Head of Tsinghua Medicine, Beijing, China. Over the past two decades, Prof. Wong has served in multiple academic and leadership positions in Singapore and Australia. Prof. Wong is a practicing ophthalmologist and retinal specialist, with a broad research portfolio on retinal diseases (e.g., diabetic retinopathy), ocular imaging, and the development and application of a range of digital technology including AI and deep learning. He has published >1,500 peer-reviewed papers and is a highly cited researcher (2018, 2020, 2021, 2022). Prof Wong has served as a Board member of numerous professional organizations, given >500 lectures internationally, and been recognized with multiple international awards, including the Arnall Patz Medal (Macula Society), the Jose Rizal Medal (Asia Pacific Academy of Ophthalmology) and the Friedenwald Award (ARVO). He has received Singapore’s President’s Science and Technology Award for application of AI in health care. He is an elected international (foreign) member of the U.S. National Academy of Medicine and the Australian Academy of Health and Medical Sciences.
| |
Krishna Yeshwant, MD, MBA, Google Ventures Krishna helps steward the GV investing team and co-leads GV’s life sciences group. Krishna led GV’s early investments in Flatiron Health, Foundation Medicine, Relay Therapeutics, Beam Therapeutics, insitro, One Medical, and Aledade. He also established GV’s incubation program, which helped start companies like ROME Therapeutics and Verve Therapeutics. Krishna was part of a team that helped in the early days of GV’s founding and led the fund’s early commitment to invest in life sciences. Earlier in his career, he helped start an electronic data interchange company acquired by Hewlett-Packard and a network security company acquired by Symantec. Krishna graduated from Harvard’s MD/MBA program where he wrote software to use imaging systems to guide surgical procedures. He went on to serve as an attending in internal medicine at Brigham and Women’s Hospital. | |
Marinka Zitnik, PhD, Harvard Medical School Marinka Zitnik is an Assistant Professor of Biomedical Informatics at Harvard Medical School with additional appointments at Harvard Data Science Initiative and Broad Institute of Harvard and MIT. Dr. Zitnik works on infusing knowledge, structure, and geometry into machine learning models. She is especially interested in using the methods to produce actionable representations for therapeutic development and precision medicine. Dr. Zitnik is an ELLIS Scholar in the European Laboratory for Learning and Intelligent Systems Society. Her research won paper and research awards from the International Society for Computational Biology, Bayer Early Excellence in Science, Amazon Faculty Research, Roche Alliance with Distinguished Scientists, Rising Star Award in Electrical Engineering and Computer Science, and Next Generation in Biomedicine Recognition. Dr. Zitnik leads Therapeutics Data Commons, an initiative to access and evaluate AI capability across therapeutic modalities and stages of drug development, and the AI4Science initiative to examine opportunities in AI and capture grand challenges to realizing those opportunities. | |
James Zou, PhD, Stanford University James Zou is an Assistant Professor of Biomedical Data Science at Stanford University. He develops machine learning methods for biology and medicine. He works on both improving the foundations of ML–by making models more trustworthy and reliable–as well as in-depth scientific and clinical applications. He has received a Sloan Fellowship, an NSF CAREER Award, two Chan-Zuckerberg Investigator Awards, a Top Ten Clinical Achievement Award, several best paper awards, and faculty awards from Google, Amazon, and Adobe. | |